A Glimmer of Hope for Patients with Acute MI and Cardiogenic Shock

Placement of a microaxial flow pump reduced mortality in patients with this dire complication of acute myocardial infarction.

Despite recent advances in treating acute myocardial infarction, patients who develop cardiogenic shock in this setting continue to experience mortality rates of 40%–50%. Use of a microaxial flow pump in these patients is theoretically attractive because it simultaneously unloads the left ventricle while increasing systemic blood flow.

In a partially manufacturer-funded, multicenter trial (NCT1633502), investigators randomized 360 patients with acute ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock to receive microaxial flow pump support for at least 48 hours or standard care (which included other support devices if necessary). All patients had undergone or were planned for emergent coronary revascularization. Median …

Reviewing Author

David J. Cohen, MD, MSc

Disclosures

Consultant/Advisory BoardMedtronic; Edwards Lifesciences; Abbott Vascular; Boston Scientific; St. Francis Hospital

Speaker’s BureauBoston Scientific; ZOLL Medical

Grant/Research SupportEdwards Lifesciences; Abbott Vascular; Boston Scientific; Corvia Medical; National Heart, Lung, and Blood Institute; Phillips, Inc.; St. Paul’s Hospital; V-Wave, Inc; ZOLL Medical; CathWorks, ANCORA

Editorial BoardsJACC; American Heart Journal; EuroIntervention; JSCAI; Structural Heart Journal

Leadership Positions in Professional SocietiesSociety of Thoracic Surgeons/American College of Cardiology TVT Registry (Co-Chair, Risk Model Development Committee); Cardiovascular Research Foundation (Co-Director, TCT Annual Meeting; Co-Director, New York Valves Annual Meeting)